Need Tally
for Clients?

Contact Us! Here

  Tally Auditor

License (Renewal)
  Tally Gold

License Renewal

  Tally Silver

License Renewal
  Tally Silver

New Licence
  Tally Gold

New Licence
 
Open DEMAT Account with in 24 Hrs and start investing now!
« Mergers and Acquisitions »
Open DEMAT Account in 24 hrs
 Govt may further sweeten Air India offer
 How India is becoming an unlikely Asian hotspot for mergers & acquisitions
 Notification No. 05/2020-Customs (ADD) Ministry Of Finance
 Deals of the day-Mergers and acquisitions March 6, 2020
 Deals of the day-Mergers and acquisitions March 2, 2020
 Mint Investment Summit - M&A in India: Challenges and opportunities
 Record Year 2019: Fintech Deals, Mergers and Acquisitions Study
 Deals of the day-Mergers and acquisitions February 28, 2020
 Deals of the day-Mergers and acquisitions February 4, 2020
 The mergers and acquisitions perspective
 Deals of the day-Mergers and acquisitions January 6, 2020

Pharma sector set for wave of mergers, acquisitions: EY
May, 31st 2016

The pharmaceuticals sector is facing an intensive period of mergers and acquisitions in the coming years, even if US firms Pfizer and Allergan recently failed to tie the knot, the corporate consultancy firm EY said Monday.

"We're going to see a high level of investments and divestments in the pharmaceuticals sector in the coming years," said Gerd Stuerz, analyst at EY.

In April, Pfizer and Allergan called off a $160-billion (144-billion-euro) tie-up to create a new world leader in pharmaceuticals ahead of Switzerland's Novartis due to a US crackdown on tax-saving mergers.

But that is unlikely to signify the end of a wave of major deals in the sector, EY said.

"Companies will sell off entire divisions or buy new ones in order to strengthen their position," said another expert Siegfried Bialojan.

In face of fierce competition, external growth is now key for many companies.

"Pharmaceutical groups can only present innovations quickly if they buy these from outside," Bialojan argued.

After a record year for M&A (mergers and acquisitions) in the pharmaceuticals sector in 2014, 2015 would have been even better if the tie-up between Pfizer and Allergan had materialised.

Bialojan predicted that mergers of a scale of around $200 billion would become the "new norm" in the sector.

A number of major deals have been signed in recent years. After its failure to acquire Allergan, Pfizer recently announced plans to buy Anacor Pharmaceuticals, a specialist in eczema treatment, for more than five billion dollars.

It is also interested in Medivation, a California-based biotechnology firm specialising in cancer treatments that is also coveted by French group Sanofi and US firm Amgen.

Also in the US, Abbott Laboratories and St. Jude Medical, leading makers of heart care and coronary devices, announced a $25 billion merger to better target the rising levels of cardiovascular disease in aging populations.

German pharmaceuticals and chemicals giant Bayer is offering 55 billion euros for Monsanto , a bid the US firm has rejected for now.

Home | About Us | Terms and Conditions | Contact Us
Copyright 2024 CAinINDIA All Right Reserved.
Designed and Developed by Ritz Consulting